Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]

The vice president and senior global program lead for Hematology and Cell Therapy at BMS provided an overview behind the mechanism and early phase 1 data of BMS-986353 in various forms of multiple sclerosis. [WATCH TIME: 4 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed how the CALLIPER trial’s lower proportion of patients with gadolinium-enhancing lesions mirrors clinical practice more closely than other progressive MS trials. [WATCH TIME: 2 minutes]

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic discussed key insights into patient characteristics and lesion differences of the CALLIPER Trial in retrospect to other studies. [WATCH TIME: 4 minutes]

After 4 years of treatment, those on cladribine demonstrated a correlation between sustained health-related quality of life, specifically physical and mental health, and cognition.

The executive vice president of research at National MS Society talked about how advancements in the field of neurology are shaping new approaches to diagnosing, monitoring, and treating multiple sclerosis. [WATCH TIME: 5 minutes]

Overall, 81.6% of patients preferred ocrelizumab over other MS treatments, with 98.1% satisfied with it overall by week 48.

The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]

The study will track patients over 36 months and use T2 lesion count and the number of serious infections as primary endpoints, with secondary endpoints including adverse events, relapse rates, and the achievement of no evidence of disease activity.

The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave clinical insights on emerging, innovative tracks at the 2025 ACTRIMS Forum and how these sessions align with recent trends in the multiple sclerosis field. [WATCH TIME: 4 minutes]

The John David Eaton Chair in Multiple Sclerosis at the University of Toronto gave an overview for the upcoming ACTRIMS Forum, highlighting key sessions, themes, and advances in the multiple sclerosis field.

The 2024 revisions to the McDonald diagnostic criteria for multiple sclerosis (MS) mark a significant advancement in the early detection and diagnosis of the disease, with new biomarkers and a broadened scope that may lead to earlier intervention and improved patient outcomes.

The professor of materials science and engineering at Cornell University and chief executive officer at Artificial Axon Labs talked about the development of artificial axons through 3D printing. [WATCH TIME: 6 minutes]

The professor of neurology at Johns Hopkins Medicine discussed the trial design of the phase 4 RENEW study assessing the long-term safety profile of mitoxantrone in multiple sclerosis. [WATCH TIME: 9 minutes]

The assistant professor of neurology at Johns Hopkins Medicine talked about her preclinical research in immunology to explore the intricate mechanisms controlling chronic inflammation in the central nervous system. [WATCH TIME: 5 minutes]

The professor of neurology at Johns Hopkins Medicine discussed the limited impact of current therapies on retinal atrophy rates in progressive multiple sclerosis at the 2024 ACTRIMS Forum. [WATCH TIME: 5 minutes]

The director of the Multiple Sclerosis Program at the Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed findings from a study that compared cognitive profiles between patients with multiple sclerosis and Alzheimer disease. [WATCH TIME: 5 minutes]

The assistant professor of neurology at Johns Hopkins Medicine talked about recent research that suggests activating the NLRX1 pathway could offer neuroprotection in multiple sclerosis. [WATCH TIME: 5 minutes]

The associate professor of biology at Georgetown University talked about how immune cells can communicate with brain cells to enhance repair processes, which may offer potential treatment targets for multiple sclerosis. [WATCH TIME: 5 minutes]

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 32 minutes]

The professor of neurology at Johns Hopkins Medicine talked about modeling visual systems as an area of focus in clinical trials for multiple sclerosis as it may offer insights into neurodegeneration and neuroprotection. [WATCH TIME: 6 minutes]

The associate vice president of clinical Innovation and strategy and the health equity director at National MS Society talked about leveraging data mapping to bridge healthcare gaps and promote health equity in multiple sclerosis. [WATCH TIME: 4 minutes]

The professor of epidemiology at Karolinska Institutet talked about findings from a comprehensive study on the correlation between obesity and accelerated progression of multiple sclerosis. [WATCH TIME: 8 minutes]

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania discussed preclinical research on neural repair in multiple sclerosis at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]

Following the 2024 ACTRIMS Forum, the associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided insight on the need to build creative trials for multiple sclerosis treatments. [WATCH TIME: 3 minutes]

The Melissa and Paul Anderson President’s Distinguished Professor of Neurology, Perelman School of Medicine, University of Pennsylvania, discussed the promising avenue of BTK inhibitors for addressing progressive multiple sclerosis. [WATCH TIME: 5 minutes]

A recent analysis of a phase 2 trial showed that repeated intrathecal injections of MSC therapy led to significant reductions in serum biomarkers and improvements in neurological function for progressive MS.

The medial director of Novartis talked about findings from a real-world study assessing ofatumumab treatment for multiple sclerosis presented at the 2024 ACTRIMS Forum. [WATCH TIME: 3 minutes]

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine discussed several notable presentations and topics from the 2024 ACTRIMS Forum, highlighting advances in MS care. [WATCH TIME: 9 minutes]

The postdoctoral researcher in the department of neurology at Johns Hopkins School of Medicine discussed findings from a study on the impact of indole 3-lactate supplementation in animal models of multiple sclerosis. [WATCH TIME: 4 minutes]